{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T07:28:02Z","timestamp":1778570882332,"version":"3.51.4"},"reference-count":32,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T00:00:00Z","timestamp":1648512000000},"content-version":"vor","delay-in-days":1762,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014319","name":"Society for Laboratory Automation and Screening","doi-asserted-by":"crossref","award":["Endowed Fellowship"],"award-info":[{"award-number":["Endowed Fellowship"]}],"id":[{"id":"10.13039\/100014319","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["0327077"],"award-info":[{"award-number":["0327077"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["0856492"],"award-info":[{"award-number":["0856492"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["1343991"],"award-info":[{"award-number":["1343991"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["1350197"],"award-info":[{"award-number":["1350197"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["1444100"],"award-info":[{"award-number":["1444100"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001368","name":"V Foundation for Cancer Research","doi-asserted-by":"publisher","award":["V Scholar Award"],"award-info":[{"award-number":["V Scholar Award"]}],"id":[{"id":"10.13039\/100001368","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001062","name":"Wallace H. Coulter Foundation","doi-asserted-by":"publisher","award":["Translational Research Award"],"award-info":[{"award-number":["Translational Research Award"]}],"id":[{"id":"10.13039\/100001062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009884","name":"American Academy of Implant Dentistry","doi-asserted-by":"publisher","award":["20150460"],"award-info":[{"award-number":["20150460"]}],"id":[{"id":"10.13039\/100009884","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U54CA151880"],"award-info":[{"award-number":["U54CA151880"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["slas-technology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["SLAS Technology"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1177\/2211068216681979","type":"journal-article","created":{"date-parts":[[2016,12,5]],"date-time":"2016-12-05T22:50:27Z","timestamp":1480978227000},"page":"276-288","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Optimizing Combination Therapy for Acute Lymphoblastic Leukemia Using a Phenotypic Personalized Medicine Digital Health Platform: Retrospective Optimization Individualizes Patient Regimens to Maximize Efficacy and Safety"],"prefix":"10.1016","volume":"22","author":[{"given":"Dong-Keun","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivian Y.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theodore","family":"Kee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chih-Ming","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dean","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1177\/2211068216681979_bib1","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1002\/cncr.28748","article-title":"Declining Childhood and Adolescent Cancer Mortality","volume":"120","author":"Smith","year":"2014","journal-title":"Cancer"},{"key":"10.1177\/2211068216681979_bib2","doi-asserted-by":"crossref","first-page":"5477","DOI":"10.1182\/blood-2008-01-132837","article-title":"Clinical Significance of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia and Its Relationship to Other Prognostic Factors: A Children\u2019s Oncology Group Study","volume":"111","author":"Borowitz","year":"2008","journal-title":"Blood"},{"key":"10.1177\/2211068216681979_bib3","doi-asserted-by":"crossref","unstructured":"Pui, C. H., Pei, D., Raimondi, S. C., et al. Clinical Impact of Minimal Residual Disease in Children with Different Subtypes of Acute Lymphoblastic Leukemia Treated with Response-Adapted Therapy. Leukemia 2016. DOI: 10.1038\/leu.2016.234.","DOI":"10.1038\/leu.2016.234"},{"key":"10.1177\/2211068216681979_bib4","doi-asserted-by":"crossref","first-page":"456","DOI":"10.4149\/316_150910N482","article-title":"Treatment and Prognosis of Childhood Acute Lymphoblastic Leukemia on Protocols ALL-BFM 90, 95 and ALL IC-BFM 2002: A Retrospective Single-Center Study from Olomouc, Czech Republic","volume":"63","author":"Volejnikova","year":"2016","journal-title":"Neoplasma"},{"key":"10.1177\/2211068216681979_bib5","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1200\/JCO.2015.64.6364","article-title":"Successful Therapy Reduction and Intensification for Childhood Acute Lymphoblastic Leukemia Based on Minimal Residual Disease Monitoring: Study ALL10 from the Dutch Childhood Oncology Group","volume":"34","author":"Pieters","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1177\/2211068216681979_bib6","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1200\/JCO.2009.22.2950","article-title":"Outcome of Patients Treated for Relapsed or Refractory Acute Lymphoblastic Leukemia: A Therapeutic Advances in Childhood Leukemia Consortium Study","volume":"28","author":"Ko","year":"2010","journal-title":"J Clin. Oncol."},{"key":"10.1177\/2211068216681979_bib7","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1200\/JCO.2008.16.1414","article-title":"Reinduction Platform for Children with First Marrow Relapse of Acute Lymphoblastic Leukemia: A Children\u2019s Oncology Group Study [corrected]","volume":"26","author":"Raetz","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1177\/2211068216681979_bib8","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1200\/JCO.2009.25.1983","article-title":"Long-Term Outcome in Children with Relapsed Acute Lymphoblastic Leukemia after Time-Point and Site-of-Relapse Stratification and Intensified Short-Course Multidrug Chemotherapy: Results of Trial ALL-REZ BFM 90","volume":"28","author":"Tallen","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1177\/2211068216681979_bib9","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/00043426-199302000-00010","article-title":"Cellular Pharmacology of 6-Mercaptopurine in Acute Lymphoblastic Leukemia","volume":"15","author":"Bostrom","year":"1993","journal-title":"Am. J. Pediatr. Hematol. Oncol."},{"key":"10.1177\/2211068216681979_bib10","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1089\/dna.1996.15.17","article-title":"Thiopurine Methyltransferase Pharmacogenetics: Human Gene Cloning and Characterization of a Common Polymorphism","volume":"15","author":"Szumlanski","year":"1996","journal-title":"DNA Cell Biol."},{"key":"10.1177\/2211068216681979_bib11","doi-asserted-by":"crossref","first-page":"6444","DOI":"10.1073\/pnas.94.12.6444","article-title":"Enhanced Proteolysis of Thiopurine S-Methyltransferase (TPMT) Encoded by Mutant Alleles in Humans (TPMT*3A, TPMT*2): Mechanisms for the Genetic Polymorphism of TPMT Activity","volume":"94","author":"Tai","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1177\/2211068216681979_bib12","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/s00439-002-0798-z","article-title":"Genetic Basis of Inosine Triphosphate Pyrophosphohydrolase Deficiency","volume":"111","author":"Sumi","year":"2002","journal-title":"Hum. Genet."},{"key":"10.1177\/2211068216681979_bib13","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/FPC.0b013e3282f55e2e","article-title":"Functional Characterization of Human Xanthine Oxidase Allelic Variants","volume":"18","author":"Kudo","year":"2008","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1177\/2211068216681979_bib14","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/clpt.1994.4","article-title":"Thiopurine Methyltransferase Activity in American White Subjects and Black Subjects","volume":"55","author":"McLeod","year":"1994","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1177\/2211068216681979_bib15","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S0022-3476(05)83063-X","article-title":"Altered Mercaptopurine Metabolism, Toxic Effects, and Dosage Requirement in a Thiopurine Methyltransferase-Deficient Child with Acute Lymphocytic Leukemia","volume":"119","author":"Evans","year":"1991","journal-title":"J. Pediatr."},{"key":"10.1177\/2211068216681979_bib16","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/clpt.1987.4","article-title":"Thiopurine Pharmacogenetics in Leukemia: Correlation of Erythrocyte Thiopurine Methyltransferase Activity and 6-Thioguanine Nucleotide Concentrations","volume":"41","author":"Lennard","year":"1987","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1177\/2211068216681979_bib17","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/0140-6736(90)91745-V","article-title":"Genetic Variation in Response to 6-Mercaptopurine for Childhood Acute Lymphoblastic Leukaemia","volume":"336","author":"Lennard","year":"1990","journal-title":"Lancet"},{"key":"10.1177\/2211068216681979_bib18","doi-asserted-by":"crossref","first-page":"5145","DOI":"10.1182\/blood-2013-01-480335","article-title":"Germline Genetic Variations in Methotrexate Candidate Genes Are Associated with Pharmacokinetics, Toxicity, and Outcome in Childhood Acute Lymphoblastic Leukemia","volume":"121","author":"Radtke","year":"2013","journal-title":"Blood"},{"key":"10.1177\/2211068216681979_bib19","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1007\/s13277-012-0395-2","article-title":"Impact of Methylenetetrahydrofolate Reductase (MTHFR) Polymorphisms on Methotrexate-Induced Toxicities in Acute Lymphoblastic Leukemia: A Meta-Analysis","volume":"33","author":"Yang","year":"2012","journal-title":"Tumour Biol."},{"key":"10.1177\/2211068216681979_bib20","doi-asserted-by":"crossref","first-page":"5105","DOI":"10.1073\/pnas.0800823105","article-title":"Closed-Loop Control of Cellular Functions Using Combinatory Drugs Guided by a Stochastic Search Algorithm","volume":"105","author":"Wong","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1177\/2211068216681979_bib21","doi-asserted-by":"crossref","first-page":"11464","DOI":"10.1038\/srep11464","article-title":"Preclinical Optimization of a Broad-Spectrum Anti-Bladder Cancer Tri-Drug Regimen via the Feedback System Control (FSC) Platform","volume":"5","author":"Liu","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1177\/2211068216681979_bib22","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s10456-015-9462-9","article-title":"Rapid Optimization of Drug Combinations for the Optimal Angiostatic Treatment of Cancer","volume":"18","author":"Weiss","year":"2015","journal-title":"Angiogenesis"},{"key":"10.1177\/2211068216681979_bib23","doi-asserted-by":"crossref","first-page":"065003","DOI":"10.1088\/1478-3975\/11\/6\/065003","article-title":"Discovery of a Low Order Drug-Cell Response Surface for Applications in Personalized Medicine","volume":"11","author":"Xianting","year":"2014","journal-title":"Phys. Biol."},{"key":"10.1177\/2211068216681979_bib24","doi-asserted-by":"crossref","first-page":"E2172","DOI":"10.1073\/pnas.1600812113","article-title":"Output-Driven Feedback System Control Platform Optimizes Combinatorial Therapy of Tuberculosis Using a Macrophage Cell Culture Model","volume":"113","author":"Silva","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1177\/2211068216681979_bib25","doi-asserted-by":"crossref","first-page":"3332","DOI":"10.1021\/acsnano.5b00638","article-title":"Mechanism-Independent Optimization of Combinatorial Nanodiamond and Unmodified Drug Delivery Using a Phenotypically Driven Platform Technology","volume":"9","author":"Wang","year":"2015","journal-title":"ACS Nano"},{"key":"10.1177\/2211068216681979_bib26","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1177\/2211068215579612","article-title":"Identification and Optimization of Combinatorial Glucose Metabolism Inhibitors in Hepatocellular Carcinomas","volume":"20","author":"Mohd Abdul Rashid","year":"2015","journal-title":"J. Lab. Autom."},{"key":"10.1177\/2211068216681979_bib27","doi-asserted-by":"crossref","first-page":"e1500439","DOI":"10.1126\/sciadv.1500439","article-title":"Nanodiamonds: The Intersection of Nanotechnology, Drug Development, and Personalized Medicine","volume":"1","author":"Ho","year":"2015","journal-title":"Sci. Adv."},{"key":"10.1177\/2211068216681979_bib28","doi-asserted-by":"crossref","first-page":"216rv4","DOI":"10.1126\/scitranslmed.3005872","article-title":"Cancer Nanomedicine: From Drug Delivery to Imaging","volume":"5","author":"Chow","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1177\/2211068216681979_bib29","doi-asserted-by":"crossref","first-page":"333ra49","DOI":"10.1126\/scitranslmed.aac5954","article-title":"Individualizing Liver Transplant Immunosuppression Using a Phenotypic Personalized Medicine Platform","volume":"8","author":"Zarrinpar","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1177\/2211068216681979_bib30","doi-asserted-by":"crossref","unstructured":"Ho, D., Zarrinpar, A., Chow, E. K.-H. Diamonds, Digital Health, and Drug Development: Optimizing Combinatorial Nanomedicine. ACS Nano 2016. DOI: 10.1021\/acsnano.6b06174.","DOI":"10.1021\/acsnano.6b06174"},{"key":"10.1177\/2211068216681979_bib31","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2217\/14622416.9.2.169","article-title":"Dosing Algorithm for Warfarin Using CYP2C9 and VKORC1 Genotyping from a Multi-Ethnic Population: Comparison with Other Equations","volume":"9","author":"Wu","year":"2008","journal-title":"Pharmacogenomics"},{"key":"10.1177\/2211068216681979_bib32","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/nature02626","article-title":"Moving Towards Individualized Medicine with Pharmacogenomics","volume":"429","author":"Evans","year":"2004","journal-title":"Nature"}],"container-title":["SLAS Technology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2211068216681979","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/2211068216681979","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2472630322013127?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2472630322013127?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2211068216681979","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2211068216681979","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T12:03:31Z","timestamp":1762862611000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2472630322013127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S2472630322013127"],"URL":"https:\/\/doi.org\/10.1177\/2211068216681979","relation":{},"ISSN":["2472-6303"],"issn-type":[{"value":"2472-6303","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimizing Combination Therapy for Acute Lymphoblastic Leukemia Using a Phenotypic Personalized Medicine Digital Health Platform: Retrospective Optimization Individualizes Patient Regimens to Maximize Efficacy and Safety","name":"articletitle","label":"Article Title"},{"value":"SLAS Technology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1177\/2211068216681979","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2017 Society for Laboratory Automation and Screening. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}